The cephalosporin market size has grown steadily in recent years. It will grow from $17.04 billion in 2023 to $17.69 billion in 2024 at a compound annual growth rate (CAGR) of 3.8%. The growth observed in the historical period can be attributed to factors such as the growing prevalence of bacterial infections, the increasing challenge of antibiotic resistance, a rise in surgical procedures and hospitalizations, heightened awareness among healthcare professionals, and regulatory support for the development of antibiotics.
The cephalosporin market size is expected to see steady growth in the next few years. It will grow to $20.29 billion in 2028 at a compound annual growth rate (CAGR) of 3.5%. The anticipated growth in the forecast period can be attributed to the escalating global burden of infectious diseases, the emergence of bacterial resistance, continued growth in surgical interventions, and healthcare-associated infections. Additionally, there is an increasing demand for broad-spectrum antibiotics, and evolving reimbursement policies are influencing market dynamics. Major trends expected in the forecast period include technological advancements in antibiotic development, changes in the regulatory landscape, market expansion with advanced solutions, and increased collaborations and partnerships within the pharmaceutical and healthcare sectors.
The anticipated increase in infectious diseases is poised to drive the growth of the cephalosporin market in the future. Infectious diseases encompass illnesses caused by the invasion and multiplication of pathogenic microorganisms, such as bacteria, viruses, fungi, and parasites. These diseases, including tuberculosis, malaria, and flu, contribute to the demand for cephalosporin antibiotics. Cephalosporins play a crucial role in managing and combating bacterial infections associated with various types of infections. For example, a report from the Centers for Disease Control and Prevention in March 2023 indicated a rise in tuberculosis (TB) cases in the United States, reaching 8,300 cases in 2022 compared to 7,874 cases in 2021. Thus, the growing prevalence of infectious diseases is expected to fuel the growth of the cephalosporin market.
The increase in healthcare expenditures is set to propel the growth of the cephalosporin market. Healthcare expenditures encompass all costs related to providing health services, family planning activities, nutrition programs, and emergency assistance with a focus on health. Higher healthcare expenditures contribute to the cephalosporin market by enhancing accessibility and affordability, as well as fostering research, development, and innovation in antibiotic treatments. The Centers for Medicare & Medicaid Services reported in December 2023 that US healthcare spending rose by 4.1% to $4.5 trillion, or $13,493 per person in 2022, accounting for 17.3% of the country's gross domestic product. Consequently, the rise in healthcare expenditures is driving the growth of the cephalosporin market.
The side effects associated with cephalosporin are expected to pose a hindrance to the growth of the cephalosporin market. These antibiotics, effective against bacterial infections by disrupting cell wall synthesis, come with concerns about potential side effects. Patients may experience adverse reactions, such as allergic responses or gastrointestinal issues, limiting the adoption of cephalosporin. StatPearls Publishing LLC reported in June 2023 that the incidence of cephalosporin allergy is approximately 1 to 3% of the general population. Therefore, the side effects linked to cephalosporin are restraining the market's growth.
Leading companies in the cephalosporin market are actively developing new products and therapies, including advanced-generation cephalosporins, to combat antibiotic resistance and enhance their portfolio's effectiveness against a broader spectrum of bacterial infections. Ceftobiprole, a broad-spectrum cephalosporin antibiotic, is utilized to treat various bacterial infections, including skin and soft tissue infections and pneumonia. Mast Group Ltd. launched Ceftobiprole 5µg in the MASTDISCS Antimicrobial Susceptibility Test range in July 2022, offering a strong alternative for targeted empirical therapy due to its broad range of activity, effectiveness against methicillin-resistant Staphylococcus aureus (MRSA), and favorable safety profile.
In October 2021, Sandoz International GmbH acquired the cephalosporin antibiotic business from GlaxoSmithKline PLC, solidifying its global leadership in antibiotics. Through this acquisition, Sandoz International GmbH gained rights to three established brands (Zinnat, Zinacef, and Fortum) in over 100 regions. GlaxoSmithKline PLC is a UK-based biopharmaceutical company specializing in cephalosporins.
Major companies operating in the cephalosporin market report are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., Novartis AG, AbbVie Inc., AstraZeneca PLC, Sanofi SA, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Allergan PLC, Baxter International Inc., Eisai Co. Ltd., Macleods Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Shionogi & Co Ltd., Cipla Inc., Hikma Pharmaceuticals PLC, Lupin Ltd., Zydus Lifesciences Ltd., Alkem Labs Ltd., Aurobindo Pharma Ltd., Fresenius Kabi, Aristo Pharmaceuticals Ltd., Accord Healthcare Ltd., Mankind Pharma Ltd., Qilu Anti Pharmaceutical Co. Ltd., Shandong Ruiying Pioneer Pharmaceutical Co. Ltd., Vansen Pharma Inc.
Asia-Pacific was the largest region in the cephalosporin market in 2023. The regions covered in the cephalosporin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cephalosporin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Cephalosporin refers to a class of broad-spectrum, semisynthetic-lactam antibiotics that are widely prescribed to treat diseases caused by both gram-positive and gram-negative bacteria. This class of antibiotics is commonly used to address various infections, including skin infections, strep throat, pneumonia, staph infections, tonsillitis, and bronchitis. Cephalosporins are particularly valuable for individuals allergic to penicillin, another common antibiotic.
The main types of cephalosporins are branded and generic. Branded cephalosporins are antibiotics marketed and sold under a specific brand name by pharmaceutical companies. They are utilized to treat infections caused by susceptible bacteria and can be administered via injection or oral routes. Branded cephalosporins find application in the treatment of respiratory tract infections, skin infections, ear infections, urinary tract infections, sexually transmitted infections, and other medical conditions.
The cephalosporin market research report is one of a series of new reports that provides cephalosporin market statistics, including cephalosporin industry global market size, regional shares, competitors with a cephalosporin market share, detailed cephalosporin market segments, market trends and opportunities, and any further data you may need to thrive in the cephalosporin industry. This cephalosporin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The cephalosporin market consists of sales of cefazolin, cefuroxime, cefepime, and ceftriaxone. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The cephalosporin market size is expected to see steady growth in the next few years. It will grow to $20.29 billion in 2028 at a compound annual growth rate (CAGR) of 3.5%. The anticipated growth in the forecast period can be attributed to the escalating global burden of infectious diseases, the emergence of bacterial resistance, continued growth in surgical interventions, and healthcare-associated infections. Additionally, there is an increasing demand for broad-spectrum antibiotics, and evolving reimbursement policies are influencing market dynamics. Major trends expected in the forecast period include technological advancements in antibiotic development, changes in the regulatory landscape, market expansion with advanced solutions, and increased collaborations and partnerships within the pharmaceutical and healthcare sectors.
The anticipated increase in infectious diseases is poised to drive the growth of the cephalosporin market in the future. Infectious diseases encompass illnesses caused by the invasion and multiplication of pathogenic microorganisms, such as bacteria, viruses, fungi, and parasites. These diseases, including tuberculosis, malaria, and flu, contribute to the demand for cephalosporin antibiotics. Cephalosporins play a crucial role in managing and combating bacterial infections associated with various types of infections. For example, a report from the Centers for Disease Control and Prevention in March 2023 indicated a rise in tuberculosis (TB) cases in the United States, reaching 8,300 cases in 2022 compared to 7,874 cases in 2021. Thus, the growing prevalence of infectious diseases is expected to fuel the growth of the cephalosporin market.
The increase in healthcare expenditures is set to propel the growth of the cephalosporin market. Healthcare expenditures encompass all costs related to providing health services, family planning activities, nutrition programs, and emergency assistance with a focus on health. Higher healthcare expenditures contribute to the cephalosporin market by enhancing accessibility and affordability, as well as fostering research, development, and innovation in antibiotic treatments. The Centers for Medicare & Medicaid Services reported in December 2023 that US healthcare spending rose by 4.1% to $4.5 trillion, or $13,493 per person in 2022, accounting for 17.3% of the country's gross domestic product. Consequently, the rise in healthcare expenditures is driving the growth of the cephalosporin market.
The side effects associated with cephalosporin are expected to pose a hindrance to the growth of the cephalosporin market. These antibiotics, effective against bacterial infections by disrupting cell wall synthesis, come with concerns about potential side effects. Patients may experience adverse reactions, such as allergic responses or gastrointestinal issues, limiting the adoption of cephalosporin. StatPearls Publishing LLC reported in June 2023 that the incidence of cephalosporin allergy is approximately 1 to 3% of the general population. Therefore, the side effects linked to cephalosporin are restraining the market's growth.
Leading companies in the cephalosporin market are actively developing new products and therapies, including advanced-generation cephalosporins, to combat antibiotic resistance and enhance their portfolio's effectiveness against a broader spectrum of bacterial infections. Ceftobiprole, a broad-spectrum cephalosporin antibiotic, is utilized to treat various bacterial infections, including skin and soft tissue infections and pneumonia. Mast Group Ltd. launched Ceftobiprole 5µg in the MASTDISCS Antimicrobial Susceptibility Test range in July 2022, offering a strong alternative for targeted empirical therapy due to its broad range of activity, effectiveness against methicillin-resistant Staphylococcus aureus (MRSA), and favorable safety profile.
In October 2021, Sandoz International GmbH acquired the cephalosporin antibiotic business from GlaxoSmithKline PLC, solidifying its global leadership in antibiotics. Through this acquisition, Sandoz International GmbH gained rights to three established brands (Zinnat, Zinacef, and Fortum) in over 100 regions. GlaxoSmithKline PLC is a UK-based biopharmaceutical company specializing in cephalosporins.
Major companies operating in the cephalosporin market report are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., Novartis AG, AbbVie Inc., AstraZeneca PLC, Sanofi SA, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Allergan PLC, Baxter International Inc., Eisai Co. Ltd., Macleods Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Shionogi & Co Ltd., Cipla Inc., Hikma Pharmaceuticals PLC, Lupin Ltd., Zydus Lifesciences Ltd., Alkem Labs Ltd., Aurobindo Pharma Ltd., Fresenius Kabi, Aristo Pharmaceuticals Ltd., Accord Healthcare Ltd., Mankind Pharma Ltd., Qilu Anti Pharmaceutical Co. Ltd., Shandong Ruiying Pioneer Pharmaceutical Co. Ltd., Vansen Pharma Inc.
Asia-Pacific was the largest region in the cephalosporin market in 2023. The regions covered in the cephalosporin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cephalosporin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Cephalosporin refers to a class of broad-spectrum, semisynthetic-lactam antibiotics that are widely prescribed to treat diseases caused by both gram-positive and gram-negative bacteria. This class of antibiotics is commonly used to address various infections, including skin infections, strep throat, pneumonia, staph infections, tonsillitis, and bronchitis. Cephalosporins are particularly valuable for individuals allergic to penicillin, another common antibiotic.
The main types of cephalosporins are branded and generic. Branded cephalosporins are antibiotics marketed and sold under a specific brand name by pharmaceutical companies. They are utilized to treat infections caused by susceptible bacteria and can be administered via injection or oral routes. Branded cephalosporins find application in the treatment of respiratory tract infections, skin infections, ear infections, urinary tract infections, sexually transmitted infections, and other medical conditions.
The cephalosporin market research report is one of a series of new reports that provides cephalosporin market statistics, including cephalosporin industry global market size, regional shares, competitors with a cephalosporin market share, detailed cephalosporin market segments, market trends and opportunities, and any further data you may need to thrive in the cephalosporin industry. This cephalosporin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The cephalosporin market consists of sales of cefazolin, cefuroxime, cefepime, and ceftriaxone. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Cephalosporin Market Characteristics3. Cephalosporin Market Trends and Strategies32. Global Cephalosporin Market Competitive Benchmarking33. Global Cephalosporin Market Competitive Dashboard34. Key Mergers and Acquisitions in the Cephalosporin Market
4. Cephalosporin Market - Macro Economic Scenario
5. Global Cephalosporin Market Size and Growth
6. Cephalosporin Market Segmentation
7. Cephalosporin Market Regional and Country Analysis
8. Asia-Pacific Cephalosporin Market
9. China Cephalosporin Market
10. India Cephalosporin Market
11. Japan Cephalosporin Market
12. Australia Cephalosporin Market
13. Indonesia Cephalosporin Market
14. South Korea Cephalosporin Market
15. Western Europe Cephalosporin Market
16. UK Cephalosporin Market
17. Germany Cephalosporin Market
18. France Cephalosporin Market
19. Italy Cephalosporin Market
20. Spain Cephalosporin Market
21. Eastern Europe Cephalosporin Market
22. Russia Cephalosporin Market
23. North America Cephalosporin Market
24. USA Cephalosporin Market
25. Canada Cephalosporin Market
26. South America Cephalosporin Market
27. Brazil Cephalosporin Market
28. Middle East Cephalosporin Market
29. Africa Cephalosporin Market
30. Cephalosporin Market Competitive Landscape and Company Profiles
31. Cephalosporin Market Other Major and Innovative Companies
35. Cephalosporin Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Cephalosporin Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on cephalosporin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description:
Where is the largest and fastest growing market for cephalosporin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cephalosporin market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Type: Branded; Generic2) By Route Of Administration: Injection; Oral
3) By Application: Respiratory Tract Infection; Skin Infection; Ear Infection; Urinary Tract Infection; Sexually Transmitted Infection; Other Applications.
Key Companies Mentioned: Pfizer Inc.; Roche Holding AG; Merck & Co. Inc.; Novartis AG; AbbVie Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Pfizer Inc.
- Roche Holding AG
- Merck & Co. Inc.
- Novartis AG
- AbbVie Inc.
- AstraZeneca PLC
- Sanofi SA
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Boehringer Ingelheim International GmbH
- Allergan PLC
- Baxter International Inc.
- Eisai Co. Ltd.
- Macleods Pharmaceuticals Ltd
- Sun Pharmaceutical Industries Ltd.
- Shionogi & Co Ltd
- Cipla Inc.
- Hikma Pharmaceuticals PLC
- Lupin Ltd.
- Zydus Lifesciences Ltd.
- Alkem Labs Ltd.
- Aurobindo Pharma Ltd.
- Fresenius Kabi
- Aristo Pharmaceuticals Ltd
- Accord Healthcare Ltd.
- Mankind Pharma Ltd.
- Qilu Anti Pharmaceutical Co. Ltd.
- Shandong Ruiying Pioneer Pharmaceutical Co. Ltd
- Vansen Pharma Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | March 2024 |
| Forecast Period | 2024 - 2028 |
| Estimated Market Value ( USD | $ 17.69 Billion |
| Forecasted Market Value ( USD | $ 20.29 Billion |
| Compound Annual Growth Rate | 3.5% |
| Regions Covered | Global |
